KTE-C19 is a therapy where some of the patient’s blood cells are removed, engineered to contain a compound which targets and kills the lymphoma cells, and re-injected into the patient. It requires blood to be taken from the patient and then a single intravenous administration of treated cells, which may stay active in the body and reduce relapse.
Nivolumab is a drug that works by improving the activity of T-cells (a type of white blood cells) and thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab is another drug that works in a different way to also increase the activity of T-cells. Both drugs are given by injection into the veins. It is thought these drugs when used together may be more effective than each drug on its own. If licenced, nivolumab in combination with ipilimumab will offer additional treatment option to prolong the lives of people with head and neck cancers.